CBX and other selective 11β-HSD1 inhibitors have been shown to decrease the plasma triglyceride levels in different animal models of obesity and type 2 diabetic subjects [13]–[16]. The gene discussed is CBX1; the disease is obesity due to melanocortin 4 receptor deficiency.